LU92666I2 - Dasabuvir ou un sel qui en dérive, y compris dasabuvir sodium monohydrate - Google Patents

Dasabuvir ou un sel qui en dérive, y compris dasabuvir sodium monohydrate Download PDF

Info

Publication number: LU92666I2
Authority: LU; Luxembourg
Prior art keywords: dasabuvir; sodium monohydrate; salt therefrom; salt; crystalline forms
Prior art date: 2007-09-17

Application number

LU92666C

Other languages

English (en)

French (fr)

Original Assignee

Abbvie Bahamas Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-17

Filing date

2015-02-25

Publication date

2015-11-24

2015-02-25 Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd

2015-11-24 Publication of LU92666I2 publication Critical patent/LU92666I2/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

LU92666C 2007-09-17 2015-02-25 Dasabuvir ou un sel qui en dérive, y compris dasabuvir sodium monohydrate LU92666I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US97288107P	2007-09-17	2007-09-17
US9679208P	2008-09-13	2008-09-13
PCT/US2008/076592 WO2009039134A1 (en)	2007-09-17	2008-09-17	Anti-infective pyrimidines and uses thereof

Publications (1)

Publication Number	Publication Date
LU92666I2 true LU92666I2 (fr)	2015-11-24

Family

ID=40308557

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92666C LU92666I2 (fr)	2007-09-17	2015-02-25	Dasabuvir ou un sel qui en dérive, y compris dasabuvir sodium monohydrate

Country Status (22)

Country	Link
US (3)	US8188104B2 (da)
EP (3)	EP2368882B1 (da)
JP (3)	JP5734655B2 (da)
CN (4)	CN104628655A (da)
AT (1)	ATE519746T1 (da)
CA (2)	CA2849420C (da)
CY (3)	CY1115514T1 (da)
DK (3)	DK2368882T3 (da)
ES (3)	ES2368879T3 (da)
HK (2)	HK1148273A1 (da)
HR (2)	HRP20110809T1 (da)
HU (1)	HUS1500013I1 (da)
LT (1)	LTC2203431I2 (da)
LU (1)	LU92666I2 (da)
MX (1)	MX2010002902A (da)
NL (1)	NL300729I1 (da)
NO (1)	NO2015011I1 (da)
PL (3)	PL2368882T3 (da)
PT (3)	PT2639226T (da)
RU (2)	RU2014147354A (da)
SI (2)	SI2368882T1 (da)
WO (1)	WO2009039134A1 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101552474B1 (ko) *	2007-09-17	2015-09-11	애브비 바하마스 리미티드	Ｃ형 간염 치료용 우라실 또는 티민 유도체
EP2548873A1 (en)	2007-09-17	2013-01-23	Abbott Laboratories	N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
ATE519746T1 (de)	2007-09-17	2011-08-15	Abbott Lab	Antiinfektiöse pyrimidine und anwendungen davon
CA2730517A1 (en) *	2008-07-23	2010-01-28	F. Hoffmann-La Roche Ag	Heterocyclic antiviral compounds
AU2009295981A1 (en)	2008-09-26	2010-04-01	F. Hoffmann-La Roche Ag	Pyrine or pyrazine derivatives for treating HCV
WO2010043721A1 (en)	2008-10-17	2010-04-22	Oryzon Genomics, S.A.	Oxidase inhibitors and their use
US8993808B2 (en)	2009-01-21	2015-03-31	Oryzon Genomics, S.A.	Phenylcyclopropylamine derivatives and their medical use
CN102448952B (zh) *	2009-03-25	2014-10-29	Abbvie公司	抗病毒化合物和其用途
KR20120011880A (ko)	2009-04-25	2012-02-08	에프. 호프만-라 로슈 아게	헤테로사이클릭 항바이러스성 화합물
TWI428332B (zh)	2009-06-09	2014-03-01	Hoffmann La Roche	雜環抗病毒化合物
EP2445875A2 (en)	2009-06-24	2012-05-02	F. Hoffmann-La Roche AG	Heterocyclic antiviral compound
KR20120059626A (ko)	2009-09-21	2012-06-08	에프. 호프만-라 로슈 아게	헤테로사이클릭 항바이러스 화합물
CA2812683C (en)	2009-09-25	2017-10-10	Oryzon Genomics S.A.	Lysine specific demethylase-1 inhibitors and their use
EP2486002B1 (en)	2009-10-09	2019-03-27	Oryzon Genomics, S.A.	Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
KR20120085918A (ko) *	2009-11-21	2012-08-01	에프. 호프만-라 로슈 아게	헤테로환형 항바이러스성 화합물
US9062015B2 (en) *	2009-12-14	2015-06-23	Merck Patent Gmbh	Inhibitors of sphingosine kinase
CA2780526A1 (en) *	2009-12-14	2011-06-23	F. Hoffmann-La Roche Ag	Heterocyclic antiviral compounds
WO2011106573A2 (en)	2010-02-24	2011-09-01	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106105A2 (en)	2010-02-24	2011-09-01	Oryzon Genomics, S.A.	Inhibitors for antiviral use
US9216952B2 (en)	2010-03-23	2015-12-22	Abbvie Inc.	Process for preparing antiviral compound
PT2560947T (pt)	2010-04-19	2016-11-24	Oryzon Genomics Sa	Inibidores da desmetilase específica de lisina 1 e seu uso
US9255074B2 (en)	2010-07-16	2016-02-09	Abbvie Inc.	Process for preparing antiviral compounds
WO2012009699A2 (en) *	2010-07-16	2012-01-19	Abbott Laboratories	Process for preparing antiviral compounds
US8975443B2 (en)	2010-07-16	2015-03-10	Abbvie Inc.	Phosphine ligands for catalytic reactions
KR101774742B1 (ko)	2010-07-16	2017-09-11	애브비 아일랜드 언리미티드 컴퍼니	촉매 반응용 포스핀 리간드
US9006449B2 (en)	2010-07-29	2015-04-14	Oryzon Genomics, S.A.	Cyclopropylamine derivatives useful as LSD1 inhibitors
LT2598482T (lt)	2010-07-29	2018-07-10	Oryzon Genomics, S.A.	Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas
WO2012020725A1 (ja) *	2010-08-10	2012-02-16	塩野義製薬株式会社	Ｎｐｙｙ５受容体拮抗作用を有するヘテロ環誘導体
US9061966B2 (en)	2010-10-08	2015-06-23	Oryzon Genomics S.A.	Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) *	2010-11-30	2012-06-07	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP3981395A1 (en)	2011-02-08	2022-04-13	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for myeloproliferative disorders
CN102675092B (zh) *	2011-03-14	2014-11-05	江苏中丹药物研究有限公司	一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
PE20141692A1 (es)	2011-10-20	2014-11-08	Oryzon Genomics Sa	Compuestos de (hetero) aril ciclopropilamina como inhibidores de lsd1
JP6215212B2 (ja)	2011-10-20	2017-10-18	オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎＧｅｎｏｍｉｃｓＳ．Ａ．	Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
SE1450130A1 (sv)	2011-10-21	2014-05-07	Abbvie Inc	Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
GB2506085A (en) *	2011-10-21	2014-03-19	Abbvie Inc	Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
MX360161B (es)	2012-08-21	2018-10-09	Abbvie Inc	Proceso para preparar compuestos antiviricos.
EA032913B1 (ru)	2012-10-18	2019-08-30	Эббви Инк.	Препараты производных пиримидиндиона
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
CN106065009B (zh) *	2014-06-28	2019-03-01	广东东阳光药业有限公司	作为丙型肝炎抑制剂的化合物及其在药物中的应用
WO2016105547A1 (en)	2014-12-24	2016-06-30	Concert Pharmaceuticals, Inc.	Deuterated dasabuvir
EA036086B1 (ru) *	2016-03-17	2020-09-24	Фмк Корпорейшн	Способ превращения s-энантиомера в его рацемическую форму
US11192914B2 (en)	2016-04-28	2021-12-07	Emory University	Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN108290844B (zh) *	2016-05-27	2021-04-30	深圳市塔吉瑞生物医药有限公司	一种取代的萘环化合物及药物组合物及其应用
CN110483496B (zh) *	2019-07-17	2021-05-04	杭州市西溪医院	一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
CN111518036A (zh) *	2020-04-29	2020-08-11	杭州勇诚睿生物科技有限公司	一种达沙布韦关键中间体的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4239888A (en) *	1974-11-04	1980-12-16	Pfizer Inc.	1-Phenyluracils
JPS60243017A (ja) *	1984-05-16	1985-12-03	Kyowa Hakko Kogyo Co Ltd	抗けいれん組成物
US5084084A (en)	1989-07-14	1992-01-28	Nissan Chemical Industries Ltd.	Uracil derivatives and herbicides containing the same as active ingredient
AU627906B2 (en)	1989-07-14	1992-09-03	Nissan Chemical Industries Ltd.	Uracil derivatives and herbicides containing the same as active ingredient
CA2036304C (en)	1990-02-15	2001-04-17	Takehiko Naka	Pyrimidinedione derivatives, their production and use
NL9001075A (da) *	1990-05-04	1991-12-02	Duphar Int Res
EP0489480A1 (en) *	1990-12-05	1992-06-10	Nissan Chemical Industries Ltd.	Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja)	1992-02-07	1993-08-24	Nikko Kyodo Co Ltd	肝臓障害治療薬
DE19528305A1 (de)	1995-08-02	1997-02-06	Bayer Ag	Substituierte Phenyluracile
US6380387B1 (en)	1999-12-06	2002-04-30	Hoffmann-La Roche Inc.	4-Pyrimidinyl-n-acyl-l phenylalanines
CA2392570C (en)	1999-12-06	2010-05-11	F. Hoffmann-La Roche Ag	4-pyrimidinyl-n-acyl-l-phenylalanines
IL167954A (en)	2000-02-04	2007-10-31	Sumitomo Chemical Co	History of pyrimidine
MY164523A (en) *	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
CA2476279A1 (en) *	2002-02-14	2003-08-21	Lieven J. Stuyver	Modified fluorinated nucleoside analogues
BR0316680A (pt) *	2002-11-28	2005-10-18	Schering Ag	Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
TW200505872A (en) *	2003-06-13	2005-02-16	Lg Life Science Ltd	Hepatitis C virus inhibitors
AU2004261667A1 (en) *	2003-08-01	2005-02-10	Genelabs Technologies, Inc.	Bicyclic imidazol derivatives against Flaviviridae
US7163937B2 (en)	2003-08-21	2007-01-16	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
EP1771169A1 (en) *	2004-07-14	2007-04-11	PTC Therapeutics, Inc.	Methods for treating hepatitis c
AR057986A1 (es) *	2005-11-21	2008-01-09	Japan Tobacco Inc	Compuesto heterociclico y su uso farmaceutico
ATE519746T1 (de) *	2007-09-17	2011-08-15	Abbott Lab	Antiinfektiöse pyrimidine und anwendungen davon
EP2548873A1 (en)	2007-09-17	2013-01-23	Abbott Laboratories	N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
KR101552474B1 (ko) *	2007-09-17	2015-09-11	애브비 바하마스 리미티드	Ｃ형 간염 치료용 우라실 또는 티민 유도체
CA2730517A1 (en)	2008-07-23	2010-01-28	F. Hoffmann-La Roche Ag	Heterocyclic antiviral compounds

2008
- 2008-09-17 AT AT08832330T patent/ATE519746T1/de active
- 2008-09-17 DK DK11171399T patent/DK2368882T3/da active
- 2008-09-17 PL PL11171399T patent/PL2368882T3/pl unknown
- 2008-09-17 WO PCT/US2008/076592 patent/WO2009039134A1/en active Application Filing
- 2008-09-17 CA CA2849420A patent/CA2849420C/en active Active
- 2008-09-17 ES ES08832330T patent/ES2368879T3/es active Active
- 2008-09-17 RU RU2014147354/04A patent/RU2014147354A/ru not_active Application Discontinuation
- 2008-09-17 US US12/212,323 patent/US8188104B2/en active Active
- 2008-09-17 CN CN201410659529.4A patent/CN104628655A/zh active Pending
- 2008-09-17 PL PL08832330T patent/PL2203431T3/pl unknown
- 2008-09-17 EP EP20110171399 patent/EP2368882B1/en active Active
- 2008-09-17 DK DK08832330T patent/DK2203431T3/da active
- 2008-09-17 PT PT121822779T patent/PT2639226T/pt unknown
- 2008-09-17 MX MX2010002902A patent/MX2010002902A/es active IP Right Grant
- 2008-09-17 SI SI200831329T patent/SI2368882T1/sl unknown
- 2008-09-17 EP EP12182277.9A patent/EP2639226B1/en not_active Not-in-force
- 2008-09-17 DK DK12182277.9T patent/DK2639226T3/da active
- 2008-09-17 PT PT08832330T patent/PT2203431E/pt unknown
- 2008-09-17 SI SI200830433T patent/SI2203431T1/sl unknown
- 2008-09-17 ES ES12182277.9T patent/ES2592961T3/es active Active
- 2008-09-17 CN CN201410657922.XA patent/CN104628654A/zh active Pending
- 2008-09-17 JP JP2010525103A patent/JP5734655B2/ja active Active
- 2008-09-17 CN CN201210167588.0A patent/CN102746240B/zh not_active Expired - Fee Related
- 2008-09-17 PL PL12182277T patent/PL2639226T3/pl unknown
- 2008-09-17 EP EP20080832330 patent/EP2203431B1/en active Active
- 2008-09-17 ES ES11171399.6T patent/ES2523864T3/es active Active
- 2008-09-17 CA CA2699986A patent/CA2699986C/en not_active Expired - Fee Related
- 2008-09-17 PT PT11171399T patent/PT2368882E/pt unknown
- 2008-09-17 CN CN200880113534.8A patent/CN101842360B/zh active Active
- 2008-09-17 RU RU2010114827/04A patent/RU2539570C2/ru active
2011
- 2011-03-08 HK HK11102295.5A patent/HK1148273A1/xx unknown
- 2011-10-03 HK HK11110421.5A patent/HK1156033A1/xx not_active IP Right Cessation
- 2011-11-02 HR HR20110809T patent/HRP20110809T1/hr unknown
- 2011-11-03 CY CY20111101065T patent/CY1115514T1/el unknown
2012
- 2012-04-20 US US13/451,889 patent/US8501238B2/en active Active
- 2012-10-04 JP JP2012221886A patent/JP5931683B2/ja not_active Expired - Fee Related
2013
- 2013-03-15 US US13/838,223 patent/US9139536B2/en active Active
2014
- 2014-11-12 CY CY20141100943T patent/CY1115893T1/el unknown
- 2014-11-12 HR HRP20141102 patent/HRP20141102T1/hr unknown
2015
- 2015-02-25 LU LU92666C patent/LU92666I2/xx unknown
- 2015-03-04 LT LTPA2015013C patent/LTC2203431I2/lt unknown
- 2015-03-17 HU HUS1500013C patent/HUS1500013I1/hu unknown
- 2015-03-26 CY CY2015013C patent/CY2015013I1/el unknown
- 2015-04-08 NL NL300729C patent/NL300729I1/nl unknown
- 2015-04-14 JP JP2015082240A patent/JP2015187106A/ja active Pending
- 2015-04-22 NO NO2015011C patent/NO2015011I1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP2203431B1 (en)	2011-08-10
CN104628655A (zh)	2015-05-20
CA2699986C (en)	2014-06-17
US20120244119A1 (en)	2012-09-27
CY2015013I2 (el)	2016-04-13
SI2203431T1 (sl)	2011-12-30
HK1156033A1 (en)	2012-06-01
JP2013056886A (ja)	2013-03-28
CA2849420A1 (en)	2009-03-26
SI2368882T1 (sl)	2015-02-27
HUS1500013I1 (hu)	2016-11-28
ES2523864T3 (es)	2014-12-02
EP2639226B1 (en)	2016-08-31
RU2010114827A (ru)	2011-10-27
US8501238B2 (en)	2013-08-06
NL300729I2 (da)	2016-01-07
EP2639226A1 (en)	2013-09-18
PT2639226T (pt)	2016-12-09
RU2539570C2 (ru)	2015-01-20
PT2368882E (pt)	2014-11-27
MX2010002902A (es)	2010-06-02
CN102746240A (zh)	2012-10-24
PL2368882T3 (pl)	2015-04-30
DK2639226T3 (da)	2016-12-19
DK2203431T3 (da)	2011-11-21
US20090186912A1 (en)	2009-07-23
EP2203431A1 (en)	2010-07-07
US9139536B2 (en)	2015-09-22
US20140294766A1 (en)	2014-10-02
CY1115514T1 (el)	2016-04-13
PL2639226T3 (pl)	2017-02-28
NO2015011I2 (no)	2015-04-22
ES2592961T3 (es)	2016-12-02
EP2368882B1 (en)	2014-08-13
PL2203431T3 (pl)	2012-01-31
HK1148273A1 (en)	2011-09-02
EP2368882A1 (en)	2011-09-28
CN101842360B (zh)	2014-12-17
HRP20141102T1 (en)	2015-03-13
JP2015187106A (ja)	2015-10-29
CN102746240B (zh)	2017-10-03
CY2015013I1 (el)	2016-04-13
WO2009039134A1 (en)	2009-03-26
CN101842360A (zh)	2010-09-22
NO2015011I1 (no)	2015-05-04
DK2368882T3 (da)	2014-12-01
CY1115893T1 (el)	2017-01-25
JP2010539187A (ja)	2010-12-16
NL300729I1 (da)	2016-01-07
HRP20110809T1 (hr)	2011-12-31
ES2368879T3 (es)	2011-11-23
CN104628654A (zh)	2015-05-20
JP5734655B2 (ja)	2015-06-17
ATE519746T1 (de)	2011-08-15
CA2699986A1 (en)	2009-03-26
PT2203431E (pt)	2011-10-12
LTC2203431I2 (lt)	2017-01-25
RU2014147354A (ru)	2015-07-10
JP5931683B2 (ja)	2016-06-08
RU2014147354A3 (da)	2018-07-30
US8188104B2 (en)	2012-05-29
CA2849420C (en)	2016-07-12

Publication	Publication Date	Title
LU92666I2 (fr)	2015-11-24	Dasabuvir ou un sel qui en dérive, y compris dasabuvir sodium monohydrate
CY1114925T1 (el)	2015-12-09	Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
UY30274A1 (es)	2007-11-30	Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
WO2008089105A3 (en)	2008-09-12	Antiviral nucleoside analogs
MA30725B1 (fr)	2009-09-01	Administration d'inhibiteurs de la dipeptidyl peptidase
TW200800968A (en)	2008-01-01	Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2007079199A3 (en)	2007-09-13	Substituted bis-amide metalloprotease inhibitors
DK2314594T3 (da)	2014-10-27	6-modificerede bicykliske nukleinsyreanaloger
NO20076502L (no)	2008-02-19	Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
TW200740814A (en)	2007-11-01	Compounds
DK1789398T3 (da)	2011-01-24	2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
DK1517890T3 (da)	2008-11-10	Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
MX2009011059A (es)	2009-11-26	Aminopirimidinas utiles como inhibidores de cinasas.
MA32498B1 (fr)	2011-07-03	Compositions pharmaceutiques de rosuvastatine calcium
NO20075218L (no)	2007-12-27	Dermatological compositions and salts for the treatment of dermatological diseases
MY140858A (en)	2010-01-29	Ampa receptor potentiators
TNSN07462A1 (en)	2009-03-17	Ampa receptor potentiators
WO2005118558A3 (de)	2006-02-09	Pyrimidinverbindungen und ihre verwendung
WO2007138462A3 (en)	2009-04-23	Aqueous oral formulations of risperidone
UA92343C2 (en)	2010-10-25	Ampa receptor potentiators
JO3721B1 (ar)	2021-01-31	اعطاء مثبطات ثنائي ببتيديل ببتيداز